Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering

Rhea-AI Summary

Tonix Pharmaceuticals (Nasdaq: TNXP) has announced the closing of a $4.0 million public offering. This included 3,393,600 shares of common stock and pre-funded warrants for 3,703,140 shares, priced at $0.57 per share and $0.569 per warrant. The gross proceeds from this offering total $4.0 million, before deducting fees and other expenses. The company plans to use the net proceeds for working capital, general corporate purposes, and to prepare the new drug application for its Tonmya product candidate for fibromyalgia. Dawson James Securities acted as the sole placement agent for this offering. The offering was made under an effective shelf registration statement and filed with the SEC.

Positive

• Raised $4.0 million in gross proceeds, bolstering financial position.
• Funds intended for working capital and preparation of new drug application for Tonmya, indicating strategic focus on product development.

Negative

• Potential shareholder dilution due to issuance of new shares and warrants.

Insights

Financial Analyst

Tonix Pharmaceuticals' recent public offering of $4.0 million through the sale of common stock and pre-funded warrants is a noteworthy development. This infusion of capital is intended for working capital and general corporate purposes, including the preparation of the new drug application (NDA) for their Tonmya™ product aimed at treating fibromyalgia.

From a financial perspective, the offering price of $0.57 per share indicates the company's strategy to raise cash while keeping the stock affordable for retail investors. The low exercise price of the warrants ($0.001 per share) further incentivizes warrant holders to convert them into stock, potentially boosting liquidity in the near term.

Short-term implications include improved liquidity, which could help stabilize operations and fund ongoing research and development activities. However, the dilution effect of issuing new shares might put downward pressure on the stock price until the market adjusts to the increased share count.

In the long-term, the focus on getting FDA approval for Tonmya™ is crucial. Successful approval and commercialization could significantly enhance the company’s revenue streams, making this capital raise a strategic step toward long-term growth.

Retail investors should keep an eye on the progress of the clinical trials and the FDA's feedback on the NDA, as these milestones will be key drivers for the stock price.

Medical Research Analyst

Tonix Pharmaceuticals' decision to allocate funds toward the NDA for Tonmya™ for fibromyalgia is a important move. Fibromyalgia is a chronic condition characterized by widespread musculoskeletal pain and effective treatments are in high demand. Tonmya™ has already completed two statistically significant Phase 3 studies, which is a strong indicator of its potential efficacy and safety.

The allocation of funds towards the NDA preparation reflects the company’s confidence in Tonmya’s clinical data. If approved, Tonmya™ could address an unmet need in the fibromyalgia market, potentially capturing a significant market share given the limited treatment options available.

Additionally, Tonix’s broader CNS and immunology portfolio, including treatments for conditions like acute stress reaction and cocaine intoxication, represents a diverse pipeline that could mitigate risks associated with the success of any single product.

Investors should monitor the regulatory updates and progress in the FDA approval process, as these will provide critical insights into the future viability of Tonix’s product pipeline.

CHATHAM, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced the closing of its public offering of 3,393,600 shares of its common stock and pre-funded warrants to purchase up to 3,703,140 shares of common stock in a public offering at an offering price of $0.57 per share of common stock and $0.569 per pre-funded warrant. The warrants have an exercise price of $0.001 per share and became exercisable upon issuance.

The gross proceeds of the offering are $4.0 million before deducting placement agent fees and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including the preparation of the new drug application relating to its Tonmya™ product candidate in patients with fibromyalgia, and the satisfaction of any portion of its existing indebtedness.

Dawson James Securities, Inc. acted as the sole placement agent for the offering.

Lowenstein Sandler, New York, NY, represented the Company in connection with the offering, and ArentFox Schiff LLP, Washington, DC, represented the placement agent.

This offering was made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-266982) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). The offering was made only by means of a prospectus supplement and accompanying prospectus. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering were filed with the SEC and are available on the SEC’s website located at http://www.sec.gov. Electronic copies of the preliminary prospectus supplement may be obtained from Dawson James Securities, Inc., 101 North Federal Highway, Suite 600, Boca Raton, FL 33432 or by telephone at (561) 391-5555, or by email at investmentbanking@dawsonjames.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Tonix Pharmaceuticals Holding Corp.^*

Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya¹, a product candidate for which two statistically significant Phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction as well as fibromyalgia-type Long COVID. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

*Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.

¹Tonmya™ is conditionally accepted by the U.S. Food and Drug Administration (FDA) as the tradename for TNX-102 SL for the management of fibromyalgia. Tonmya has not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the intended use of proceeds from the public offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contact

Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 904-8182

Peter Vozzo
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505

Media Contact

Katie Dodge
LaVoieHealthScience
kdodge@lavoiehealthscience.com
(978) 360-3151

FAQ

What is the value of the public offering closed by Tonix Pharmaceuticals?

Tonix Pharmaceuticals closed a $4.0 million public offering.

How many shares were issued in Tonix Pharmaceuticals' public offering?

Tonix Pharmaceuticals issued 3,393,600 shares of common stock and pre-funded warrants for 3,703,140 shares.

What is the offering price for Tonix Pharmaceuticals' shares and warrants?

The offering price is $0.57 per share of common stock and $0.569 per pre-funded warrant.

What will Tonix Pharmaceuticals use the proceeds from the offering for?

The proceeds will be used for working capital, general corporate purposes, and preparation of a new drug application for Tonmya.

Who acted as the placement agent for Tonix Pharmaceuticals' offering?

Dawson James Securities acted as the sole placement agent for the offering.

When did Tonix Pharmaceuticals announce the closing of its public offering?

Tonix Pharmaceuticals announced the closing of its public offering on July 10, 2024.